Core Insights - Goldman Sachs Conviction List features top stock picks for institutional and high-net-worth clients, highlighting companies with strong growth and income potential [1][2] - Five dividend-paying companies have been on the Conviction List for extended periods, all rated as Buy by Goldman Sachs [1] Company Summaries - **Bank of America (NYSE: BAC)**: - Dividend yield of 2.06% - Target price set at $67 - On the Conviction List for 362 days - Operates in Global Markets, Global Banking, Global Wealth & Investment Management, and Consumer Banking segments [1][2] - **Johnson & Johnson (NYSE: JNJ)**: - Dividend yield of 2.10% - Target price set at $250 - On the Conviction List for 275 days - Focuses on pharmaceuticals, biotechnology, and medical devices across Innovative Medicine and MedTech segments [1][2] - **Huntington Ingalls Industries (NYSE: HII)**: - Dividend yield of 1.33% - Target price set at $425 - On the Conviction List for 214 days - Engages in designing and constructing military ships and offers various naval nuclear support services [1][2] - **Duke Energy (NYSE: DUK)**: - Dividend yield of 3.37% - Target price set at $141 - On the Conviction List for 214 days - Operates in Electric Utilities and Infrastructure and Gas Utilities and Infrastructure segments [1][2] - **Kontoor Brands (NYSE: KTB)**: - Dividend yield of 3.09% - Target price set at $84 - On the Conviction List for 214 days - A global lifestyle apparel company with brands like Wrangler and Lee [1][2]

Johnson & Johnson (J&J) has chosen Pennsylvania as home to its new $1bn cell therapy manufacturing facility, as the Trump administration looks to onshore drug production to the US amid growing global competition. Once operational, the Montgomery County-based, next-generation production site will create more than 500 skilled biomanufacturing roles. The facility’s development will also open up 4,000 construction positions. The Pennsylvania facility will be J&J’s eleventh site within the state, which is alre ...

Core Insights - Halozyme Therapeutics (HALO) reported a fourth-quarter 2025 adjusted loss of 24 cents per share, significantly below the Zacks Consensus Estimate of earnings of $2.15, and down from adjusted earnings of $1.26 per share in the same quarter last year [1][6] - The decline in earnings was primarily attributed to a $2.42 per share unfavorable impact from acquired IPR&D expenses related to the Surf Bio acquisition [1] Revenue Performance - Total revenues for the fourth quarter increased by 52% year over year to $451.8 million, surpassing the Zacks Consensus Estimate of $449 million [2] - The growth in revenue was driven by increased product sales and higher royalty payments, with royalty revenues totaling $258 million, up 51% from the previous year [4][6] Product Sales and Royalties - Product sales reached $122.7 million in the fourth quarter, reflecting a 54.5% increase year over year, although it fell short of the model estimate of $123.2 million [7] - Revenues under collaborative agreements were $71.1 million, marking a 47.5% year-over-year increase [7] Financial Metrics - Adjusted EBITDA for the quarter was $21.9 million, a significant decrease from $195.8 million in the same quarter last year [8] - As of December 31, 2025, the company had cash, cash equivalents, and marketable securities totaling $145.4 million, down from $702 million as of September 30, 2025 [8] Full-Year Results and Guidance - For the full year 2025, Halozyme generated revenues of $1.39 billion, a 38% increase year over year, with adjusted earnings of $4.15 per share, down from $4.23 per share in the previous year [9] - The company expects total revenues for 2026 to be between $1.71 billion and $1.81 billion, indicating year-over-year growth of 22% to 30% [10] - Royalty revenues for 2026 are anticipated to be in the range of $1.13 billion to $1.17 billion, reflecting a year-over-year growth of 30% to 35% [10] Future Expectations - Adjusted EBITDA for 2026 is projected to be between $1.125 billion and $1.205 billion, representing a year-over-year increase of 71% to 83% [11] - Adjusted earnings per share for 2026 are expected to be in the range of $7.75 to $8.25, indicating growth of 87% to 99% year over year [11] - Management anticipates a 5% to 10% decrease in royalty revenues for the first quarter of 2026 compared to the fourth quarter of 2025 due to annual contract rate adjustments [12]

Core Insights - Stocks increased on Wednesday, primarily driven by Big Tech, with Nvidia shares rising 2% following a multiyear partnership with Meta for data center chip usage [1] - WTI crude oil prices rose by 3.4% due to concerns over potential U.S.-Iran hostilities, impacting costs across various sectors [1] - Financial stocks rebounded after a previous decline, with a shift in perception regarding AI's role in enhancing productivity rather than replacing jobs [1] Company-Specific Summaries - Palo Alto Networks experienced a 7.3% decline despite exceeding quarterly expectations, as concerns about AI impacting market share persist; however, the CEO believes AI will ultimately benefit the company [1] - Bristol Myers' stock increased by 27% over three months, driven by the FDA approval of the heart medication Camzyos, but challenges in the Alzheimer's drug trials have raised concerns about future performance [1] - Jim Cramer is considering replacing Bristol Myers with Johnson & Johnson or another high-quality stock due to uncertainties surrounding the company's drug trials [1] Additional Stocks Mentioned - Stocks discussed in the rapid-fire segment included Western Digital, Palantir, Cadence Design Systems, and Analog Devices [1]

The facility is part of the company's plans to invest $55 billion in U.S. manufacturing, research and development and technology through early 2029. ...

J&J to invest $1 billion in new Pennsylvania plant amid US manufacturing push | ReutersSkip to main content[Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv]Item 1 of 2 A Johnson & Johnson banner is displayed on the front of the New York Stock Exchange (NYSE) in New York City, in New York City, U.S., December 5, 2023. REUTERS/Brendan McDermid[1/2]A Johnson & Johnson banner is displayed on the front of the New York Stock Exchange (NYSE) in New York City, in New Y ...

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) (the "Company†), healthcare's leading, most comprehensive innovation powerhouse, today announced a more than $1 billion investment in a next generation cell therapy manufacturing facility in Montgomery County, Pennsylvania. This new facility will further expand the Company's U.S. manufacturing capacity as it advances its industry leading portfolio and pipeline of transformational medicines for cancer, immune-mediated and ne. ...

Verizon vs Johnson & Johnson: Which Dividend Hike Winner Is the Better Buy? - 24/7 Wall St.[S&P 5006,863.00 +0.16%][Dow Jones49,611.00 +0.09%][Nasdaq 10024,778.20 +0.23%][Russell 20002,649.42 +0.06%][FTSE 10010,678.40 +0.99%][Nikkei 22557,198.00 +0.25%][Investing]# Verizon vs Johnson & Johnson: Which Dividend Hike Winner Is the Better Buy?### Quick ReadVerizon (VZ) offers a 5.8% yield but carries $158B in debt. Johnson & Johnson (JNJ) provides a 2.1% yield with stronger growth.Verizon's dividend grew 2.04% ...

Core Insights - Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) has received Breakthrough Therapy Designation from the U.S. FDA for treating advanced head and neck squamous cell carcinoma in patients who have progressed after platinum-based chemotherapy and PD-1/PD-L1 inhibitors [1][2] Group 1: FDA Designation and Clinical Data - The Breakthrough Therapy Designation is based on clinical data showing rapid and durable responses in heavily pretreated patients, indicating a significant need for new therapies in this area [1][2] - The designation expands the application of RYBREVANT FASPRO™ beyond its current approval for non-small cell lung cancer [1][2] - The clinical activity supporting this designation comes from the Phase 1b/2 OrigAMI-4 study, which demonstrated promising results in a challenging patient population [1][2] Group 2: Treatment Mechanism and Patient Impact - RYBREVANT FASPRO™ targets both epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition (MET) pathways, which are overexpressed in HPV-unrelated recurrent or metastatic head and neck squamous cell carcinoma [1][2] - The dual targeting approach has shown meaningful clinical benefits in lung cancer, with the aim of improving patient outcomes in head and neck cancer as well [1][2] Group 3: Ongoing Studies and Future Directions - RYBREVANT FASPRO™ is currently being evaluated in the ongoing Phase 3 OrigAMI-5 study, which compares its efficacy in combination with pembrolizumab and carboplatin against standard treatments [1][2] - The FDA's Breakthrough Therapy Designation aims to expedite the development and regulatory review process for therapies that show substantial improvement over existing options [1][2] Group 4: Background on Head and Neck Cancer - Head and neck squamous cell carcinoma accounts for over 90% of head and neck cancer cases and approximately 4.5% of all cancers globally, with a significant portion being HPV-negative, which is associated with poorer prognosis [1][2] - Despite advancements in treatment, many patients progress to advanced, recurrent, or metastatic disease, highlighting the urgent need for new therapeutic options [1][2]

AC Immune (ACIU) has disclosed that its partner Janssen Pharmaceuticals of Johnson & Johnson (JNJ) has temporarily paused enrollments in a mid-stage trial for their jointly developed Alzheimer’s candidate ACI-35.030/JNJ-2056. The companies are advancing ACI-35.030/JNJ-2056 as part of a licensing ...